Introduction
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Transition metal coordination complexes offer a variety of electronic and structural features for the design of therapeutic agents, including the choice of the metal and its oxidation state, the number and types of coordinated ligands, and their coordination geometries. [1] [2] [3] [4] [5] [6] [7] [8] [9] The heavier, third-row (5d) 30 transition elements in particular tend to exhibit slow ligand exchange kinetics and so might reach biological target sites with at least some of the initial ligands still bound. Organometallic arene and cyclopentadienyl complexes are attractive [10] [11] [12] [13] since their potential amphiphilicity can be 35 beneficial for drug transport and target recognition. Subtle changes in structure can lead to dramatic changes in chemical reactivity and biological activity. For example, certain inert N,N΄-chelated half-sandwich organometallic iodido Os II arene azopyridine complexes exhibit potent in vitro and in vivo 40 anticancer activity. 14, 15 Their mechanism of action is different from that of N,O-chelated Os II arene picolinate complexes which can hydrolyze and then bind to DNA bases, 16 with DNA being a likely target, as it is for cisplatin. 17, 18 In contrast, with the strong π-acceptor azopyridine present, Ru II 45 arene complexes with iodide as the monodentate ligand are relatively inert towards substitution reactions and appear to be activated by redox reactions, for example with glutathione. 19 Other than glutathione, the couple NADH and oxidized nicotinamide adenine dinucleotide (NAD + ) is also an 50 important part of the cellular redox balance system. 20 
Under physiological conditions, the ratio of [NADH]/[NAD + ] in cells
is low. 21 The cellular concentration of free NADH is in the nanomolar range, 21 which makes it a potential and sensitive target for anticancer drugs. 55 Early work by Steckhan 22 and Fish 23 demonstrated an efficient process for the regeneration of NADH from NAD + using formate as an hydride source and rhodium catalysts.
Similarly we have shown that ruthenium arene anticancer complexes can reduce NAD + regioselectively to NADH 60 through transfer hydrogenation. 24 Recent studies have shown that both organometallic Ru II arene complexes and Ir III Cp* complexes can oxidize NADH to NAD + . [25] [26] [27] However, there are no reports of osmium complexes as transfer hydrogenation catalysts in aqueous solution. 65 There are some intriguing differences between the chemical properties of organometallic Ru II and Os II arene complexes even though their three-dimensional structures can be almost identical. 28 Figure 1 ). 65 Crystallographic data are listed in Table S1 and selected bond lengths and angles in In addition, the two enantiomers are partially solvated by one dichloromethane and two water molecules in the asymmetric unit. The osmium complex shows a pseudo-octahedral "piano-stool" structure with the p-cymene ligand π-bonded to the metal ion and Figure S2 .
Aquation, pK a of aqua complexes and binding to 9-ethylguanine 20 The possible activation of these complexes by aquation and their interaction with 9-ethylguanine (9-EtG), a model DNA nucleobase, were studied by 1 The pK a value of the aqua adduct (14A) was determined by 1 H NMR spectroscopy ( Figure 2A) 36 The low pK a value obtained for the aqua adduct suggests that the hydroxido adduct will be the predominant species under physiological conditions. The pK a value of 2.6 for the dimethylamine substituent on the iminopyridine chelating ligand Impy-NMe 2 is the first reported 
Anticancer Activity
90
The activity of all sixteen osmium arene iminopyridine complexes towards the A2780 human ovarian cancer cell line was determined and of selected complexes towards the A549 human lung cancer cell line (Table 1 ). They exhibit a broad range 95 of anticancer activity with IC 50 values (the concentration that inhibits cell growth by 50%) towards A2780 cells ranging from 0.14 µM for [Os(η 6 -bip)(Impy-NMe 2 )I]PF 6 (5) to 35.5 µM for
[Os(η 6 -p-cym)(OMe-Impy-NMe 2 )I]PF 6 (8) (Table 1A) . When the ortho -OMe substituent on the pyridine ring in 8 was replaced by 100 H in [Os(η 6 -p-cym)(Impy-NMe 2 )I]PF 6 (6), the anticancer activity increased 44-fold (IC 50 decreased from 35.5 µM to 0.80 µM). This trend was also observed when biphenyl is the arene and the monodentate ligand is chloride where a 35-fold increase in anticancer activity was observed. Anticancer efficacy was also 105 observed towards A549 cells. A significant enhancement in activity was obtained by combination treatment with Lbuthionine-sulfoximine (L-BSO), a specific inhibitor of γ-glutamylcysteine synthetase (Table 1B) . L-BSO depletes intracellular glutathione, which plays an important role in the 110 maintenance of the redox balance in cancer cells.
115 60 
Induction of Reactive Oxygen Species (ROS) in Lung Cancer Cells
Os
II arene azopyridine complexes can increase ROS levels in cancer cells. 14 Consequently, the effect of iminopyridine complexes on cellular ROS levels was also investigated. The level of ROS induced in A549 human lung cancer cells by 65 osmium complexes 6 and 14 was monitored using the probe 2,7-dichlorodihydrofluorescein-diacetate (DCFH-DA). This hydrolyzes to 2,7-dichlorodihydrofluorescein (DCFH) in live cells, and in turn is oxidized to 2,7-dichlorofluorescein (DCF) in the presence of ROS, exhibiting a green fluorescence. 37, 38 Using 70 this probe, the level of general oxidative stress induced in A549 cells by 6 and 14 was determined. The accumulation of ROS during combined exposure to 6 or 14 with L-BSO was also studied. (Table 1B) . L-BSO alone at a dose of 50 µM had no significant effect on the increase of ROS (C+L-BSO, Fig.4 ) and the growth of A549 30 cancer cells, but greatly enhanced the cytotoxicity of osmium iminopyridine complexes towards A549 cancer cells.
Oxidation of NADH to NAD +
35
After observing the increase in ROS levels in cells induced by osmium iminopyridine complexes, we investigated reactions of the complexes with potential cellular reducing agents. It was found that 6 and 14 do not catalytically oxidize GSH, in contrast to their ruthenium azopyridine iodido analogues ( Figure S4 periods of incubation at 310 K.
LC-MS was also employed to analyse the products from the reaction between NADH (0.5 mM) and 14A (0.5 mM) after incubation at 310 K for 24 h. The decrease in intensity of the were observed after the reaction with 14A ( Figure S7 ).
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The reaction of the chlorido complex 14 with NADH (8 mol equiv) was monitored by UV-Vis over 18 h at 310 K in a phosphate buffer pH 7.4 ( Figure 6 ). The kinetic experiment showed an isosbestic point at 300 nm corresponding to the oxidation of NADH to NAD + and another isosbestic point at 432 95 nm related to the aquation of 14, suggesting that the aquation of the chlorido complex 14 accompanies the oxidation. The formation of NAD + was confirmed by a decrease in intensity of the characteristic NADH band at 338 nm and the simultaneous increase in intensity at 260 nm. were recorded at intervals of 20 min. Inset: (B) Dependence of the turnover number (TON) of complex 14 (0.025 mM) on the mol ratio of NADH. The reaction was followed by the decrease in intensity of the NADH absorption band at 338 nm. 5 The dependence of the oxidative activity of 14 on the concentration of NADH in solution was studied by following the conversion of 2 and 8 mol equivalents of NADH to NAD + ( Figure S8A ) under the same conditions described above. The rate of reaction of 14 (25 µM) was similar for reactions of 2 and 8 10 mol equiv NADH suggesting that the formation of an initial adduct is rate-limiting. An increase in NADH concentration resulted in higher turnover numbers for complex 14 ( Figure 6B) .
The NAD + /NADH ratio after 18 h was determined to be 0.14 for the reaction between 14 and 2 equiv of NADH, 0.11 for 4 15 equiv, 0.12 for 6 equiv and 0.13 for 8 equiv, respectively. The rate of oxidation of NADH (8 mol equiv) was the same in the presence of either 25 µM or 10 µM 14 ( Figure S8B ). The control solutions showed a slight decomposition of the NADH under these conditions attributable to the effect of phosphate buffer, 20 consistent with previous reports. 39, 40 Since the instability of the osmium hydride adduct formed by reaction with NADH might be due to protonation and liberation of H 2 , 41 an attempt was made to detect H 2 as a product by gas chromatography. However, none was detected (for To investigate whether aquation is a necessary step for 14 to oxidize NADH to NAD + , the reaction of 14 (0.1 mM) and NADH (0.4 mM) was carried out under three conditions: (1) without 90 NaCl, (2) with 100 mM NaCl (3) with 500 mM NaCl. The resulting NMR spectra after 24 h incubation at 310 K are shown in Figure 9 . The extent of aquation decreased from 99% to 11% and 1% at NaCl concentrations of 0 mM, 100 mM and 500 mM, respectively. After 24 h incubation with NADH at 310 K, the same amount of NAD + product (40 ± 3%) was observed for each 10 of these three solutions (Figure 9 ), this result indicating that NADH can react directly with the chlorido complex. Since complex 14 appeared to oxidize NADH by hydride transfer, we studied the effect of complex 14 on the NAD + /NADH ratio in human ovarian A2780 cancer cells. After 
Electrochemistry
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Cyclic voltammetry studies of iodido complexes 3 and 6, and chlorido complexes 10 and 14 together with 3 and 10 showed that these compounds underwent two irreversible electrochemical reductions in dimethylformamide with potentials ranging from -0.58 to -0.76 V for the first and -0.82 to -1 V for the second. 30 Subtle variations in the CV morphology and forward-reverse peak separations for the different complexes suggests some small differences in heterogeneous electron transfer kinetics ( Figure  S9 ).
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Discussion
Aquation and Binding to 9-Ethylguanine
The chlorido complex 14 [Os(η 6 -p-cym)(Impy-NMe 2 )Cl]PF 6 40 hydrolysed almost completely after 24 h in water at 310 K, whereas the iodido complex 6 [Os(η 6 -p-cym)(Impy-NMe 2 )I]PF 6 was only ca. 50% hydrolysed. This is consistent with the expected strengthening of the Os-halide bond for the heavier halides. However, both these complexes are much less stable in 45 water than the analogous azopyridine complexes. 14 The pK a of the aqua adduct 14A was determined to be 5.2, which implies that the major product of aquation at physiological pH (7.4) will be the hydroxido adduct. This may account for the low extent and slowness of binding to the nucleobase 9-ethyl 50 guanine (only 19% after 38 h of incubation at 310K, Figure 2) , since Os-OH bonds are expected to be much less reactive than Os-OH 2 bonds. We chose to study guanine as the nucleobase since G N7 is the most electron-dense site on DNA and is a known target for platinum anticancer drugs. 42 55 The findings for guanine binding suggest that DNA (and RNA) could be a target for osmium iminopyridine complexes, but the extent of binding of 14 to 9-EtG was much less than for the previously reported osmium picolinate DNA-targeted complexes, 16 which suggests that other targets may be more 60 important. The contrast between these iminopyridine complexes and their isoelectronic azopyridines analogues is quite striking. The azopyridine complexes do not readily hydrolyse and do not bind to guanine. In accordance with this, the azopyridines appear to exert their anticancer activity partly by redox mechanisms. We 65 also investigated whether redox mechanisms are important for iminopyridine complexes (vide infra).
Structure-Activity Relationships (SAR) for Human Ovarian Cancer Cells
70
When the anticancer activity of osmium arene phenyliminopyridine complexes with various substituents on the phenyl ring is compared with their phenylazopyridine analogues, the correlation coefficient is low (Figure 10 ), which suggests that 75 the mechanism of action is different for these two families of osmium anticancer complexes. For a subset of 8 of the 11 complexes however, there is a stronger correlation, Figure 10 . The iminopyridine complexes bearing a biphenyl arene exhibit higher anticancer activity towards A2780 cells than their p-80 cymene analogues (Table 1 , Chart 1). It seems likely that the greater hydrophobicity of the biphenyl complexes enhances cell uptake, although intercalation into DNA may also contribute if DNA is a target. 
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In general, the chlorido iminopyridine complexes are as active or more active than their iodido analogues. This contrasts with the azopyridine series for which the opposite is true, except for those with a -NMe 2 electron-donating substituent in the phenyl ring of the phenyliminopyridine ligand. For the inert 15 azopyridine complexes, addition of an ortho substituent such as CF 3 or Cl on the pyridine ring maintained or increased the anticancer activity. However, in the present case, ortho functionalization of the pyridine ring with a methoxy group decreased the anticancer activity significantly (Table 1) . Unlike 20 the azopyridine complexes, the Os-Cl/I bond is reactive in iminopyridine complexes and an ortho substituent may hinder the reactivity. Substitution reactions at the osmium centre may therefore be important in the mechanism of action of iminopyridine complexes. 25 Additionally, it is notable that 6 and 14 are more potent anticancer complexes than previously-reported ruthenium and osmium arene complexes which bind more strongly to DNA bases and appear to have DNA as a major target.
16, 44 Redox mediated mechanisms of activity may be more effective since 30 they can affect multi-specific targets in cells. (Fig. 3) . Although ROS are 45 generally believed to be toxic to cells, they act as a 'doubleedged sword' for the proliferation of cells. When the ROS level in cells is up-regulated on a small scale, ROS may contribute to the proliferation; if the ROS level is raised further, it can cause DNA damage which will induce cell 50 cycle arrest and apoptosis. 48 Therefore selectivity to cancer cells rather than normal cells can be achieved by increasing the ROS levels because the basal ROS levels in cancer cells are higher than in normal cells. These increases in ROS levels provide a basis for a strategy involving combination treatment 55 of 6 or 14 with the glutathione synthesis inhibitor buthionine sulfoximine (L-BSO), Fig. 4 .
Accumulation of ROS in Cancer Cells
Because the GSH concentration is 100-10,000 fold higher in cells compared to other reductants (e.g. NADH, NADPH and thioredoxin), the level of GSH usually determines the steady-state 60 value of intracellular redox potentials. 49 However, complexes 6 and 14 do not readily oxidize GSH unlike ruthenium azopyridine analogues. 14 The half-wave reduction potentials of osmium complexes 3, 6, 10 and 14 in dimethylformamide of -0.58 to -0.76 V and -0.82 to -1 V are more negative than those of the 65 ruthenium azopyridine complexes, 19 indicating that the iminopyridine complexes are more difficult to reduce, perhaps explaining why no reaction was observed with GSH ( Figures S4  and S9 ). In contrast, novel reactions with the reduced coenzyme NADH, a stronger reducing agent than GSH, were observed. The current work appears to be the first detection of an osmium(II) hydride NMR peak for an osmium hydride in an aqueous solution. [56] [57] [58] [59] [60] [61] [62] [63] [64] These findings suggest that osmium arene complexes can modulate the redox balance in cells by a novel mechanism. 95 1 H NMR studies show that complexes 6 and 14 are more effective in oxidising NADH than 8 and 16 after 24 h incubation at 310K ( Figure S5 ). This may be due to the steric hindrance exerted by the methoxy substituent in the ortho-position of the iminopyridine chelating ligand for 8 and 16. This trend is also 100 observed for the anticancer activity of these compounds: 6 and 14 are ca. 20 times more potent than 8 and 16. It is possible therefore that NADH oxidation is involved in the mechanism of anticancer activity of these osmium iminopyridine anticancer complexes. A possible mechanism for the oxidation of NADH in the 105 presence of these iminopyridine complexes involves hydride transfer to Os followed by protonation of bound hydride, We conclude from these studies that the anticancer activity of these osmium arene iminopyridine complexes may involve the modulation of redox pathways in cancer cells by a novel mechanism. In addition, we have shown that the rational design of the chelating ligands and structure of the Os II arene 75 complexes plays an important role in controlling the reactivity and biological behaviour of these anticancer drugs. 
